Your session is about to expire
← Back to Search
JNJ-63733657 for Alzheimer's Disease (Autonomy Trial)
Autonomy Trial Summary
This trial will test whether a new drug can slow down Alzheimer's disease.
Autonomy Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowAutonomy Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Autonomy Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been experiencing a slow decline in my memory and thinking skills for the past 6 months.I have been experiencing a slow decline in my memory and thinking skills for the past 6 months.Your Hachinski Ischemic Scale score is more than 4.I have been diagnosed with MCI or dementia not caused by Alzheimer's.You need to have a positive tau PET scan result.I have early Alzheimer's with worsening memory over the last 6 months.My CNS medication has been stable for 2 months, and I don't use benzodiazepines.My dementia rating is 2 or higher.Your score on the Geriatric Depression Scale (GDS) is higher than 12.I agree not to donate sperm during and up to 4 months after the study.
- Group 1: JNJ-63733657 High-dose
- Group 2: JNJ-63733657 Low-dose
- Group 3: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does the FDA sanction JNJ-63733657 for use?
"JNJ-63733657's safety was assigned a 2, as there is clinical evidence indicating its security but no studies that confirm the drug's efficacy."
What is the estimated participant population for this research project?
"To facilitate this clinical trial, 420 individuals must be recruited who meet the set requirements. Those interested can register at Parkwood Institute in London, Ontario or Alzheimers Research and Treatment Center in Wellington, Florida."
Who is eligible to enroll in this research initiative?
"This clinical trial seeks 420 patients aged between 55 and 80 suffering from dementia. Prospective enrollees must demonstrate symptoms of Early Alzheimer's disease, have a positive tau PET result, be literate with at least 5 years of formal education, possess a study partner that is adequately educated to participate in the research and provide support for the patient during treatment, as well as males agreeing not to donate sperm within 16 weeks following their last dose of medication."
Is it possible for those over 25 to partake in the experiment?
"The age limits for this medical trial are 55 and 80 respectively, as per the requirements of eligibility."
How widely is the research being conducted across North America?
"This scientific investigation is accepting participants at 59 sites, with major hubs in London, Wellington and Providence. To minimize transportation demands for volunteers involved in the study, it is suggested to select a trial location nearby."
Is enrollment in this trial open presently?
"Affirmative. According to information on clinicaltrials.gov, this research is presently recruiting patients that were initially posted on June 1st 2021 and most recently edited in November 9th 2022. 420 individuals are being accepted from 59 diverse sites for the trial."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What questions have other patients asked about this trial?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger